Germany: Boehringer Ingelheim signs option to acquire Trutino Biosciences

Germany-based Boehringer Ingelheim, a leading biopharmaceutical company, has signed an option to acquire Trutino Biosciences (Trutino), a San Diego-based pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Under the agreement, Boehringer Ingelheim reserves the right to purchase all shares of Trutino once specified…

You must be a HMI Subscriber to view this content.

Subscribe Now »